List view / Grid view
An assay is an analytical procedure in laboratory medicine, pharmacology and molecular biology for measuring the activity of a target entity.
Ensure reproducibility with TruBIOME™ - the unique approach to generating research model colonies, which allows you complete control over their microbiome, from conception to cohort delivery.
Osteoarthritis (OA) is a painful and debilitating disease of articular joints.1,2 Its clinical prevalence is as high as 21.6 percent of the population in the United States,3 which constitutes direct health costs of over 80 billion US dollars annually.4
The landscape of cancer treatment has changed dramatically in the last seven years, beginning with the approval of Ipilmumab in 2011, the first immunotherapy drug. Efforts to unsheathe the tumour cells of their protective microenvironment and expose them to an active immune response have delivered several monoclonal antibodies (mAbs) that…
Over the past 30 years, one strategy the pharmaceutical industry has adopted in the drug discovery process has been to “fail early, fail often”.1,2 As most molecules in the early stages of drug discovery will have sub-optimal characteristics, significant modification is necessary to improve their properties.
Current technologies that measure molecular interactions for drug discovery slow down and complicate screening. Dianthus is the answer to the demands for fast, non-stop, highly sensitive hit identification, hit validation and lead optimisation.
In this In-Depth Focus: the importance of characterising chemical starting points of drugs using appropriate in vitro ADME-toxicity assays, and why do we have no effective treatments for osteoarthritis?
In this issue: AI-driven automated chemistry as a tool to accelerate drug discovery processes, the shifting landscape of immuno-oncology, and how lipid molecules provide an insight into biological research.
Learn more about an emerging high-throughput method for identifying and isolating rare cells secreting antigen-specific antibodies.
18 February 2019 | By Tecan and Ncardia
Ncardia, will discuss the application of human iPSC-derived cell-based assays and high throughput screening for drug discovery and development.
A microscopy assay has shown the repair mechanism involved in the activation of a protein called Rho, used to plug leaky biological barriers in the body...
An assay assessing the level of programmed death ligand 1 (PD-L1) could help to determine the method of treatment for lung cancer patients...
Researchers have developed a method using PET imaging along with 18F-fluorofuranylnorprogesterone to analyse the efficacy of breast cancer treatments...
17 January 2019 | By IntelliCyt, a Sartorius Company
Multiplexed approach to measure T-cell activation, proliferation and quantify cytokine release in a single well
SB Drug Discovery shows the validation of fluorescence and automated electrophysiology assays designed to assess agonists, antagonists and allosteric modulators of these receptors, culminating in a high-throughput electrophysiology assay suited to assessing multiple GABAA receptor subtypes on a single assay plate.
The webinar presented an overview of the pre-clinical milestones, the current status of the global drug pipeline and a description of a number of novel drugs undergoing clinical trials.
